Treatment of Endometrial Cancer Utilizing Pathology Intraoperative Consultation to Determine Extent of Surgical Staging
- All patients must be surgical candidates for complete hysterectomy and bilateral
salpingo-oophorectomy and pelvic and aortic lymphadenectomy.
- Patients must have a histologically confirmed diagnosis of endometrial cancer and no
clinical evidence of extra-uterine disease on preoperative evaluation.
- Preoperative evaluation to rule-out extra-uterine disease may include CT scan, MRI,
or ultrasound. Preoperative imaging is not mandatory for study enrollment.
- Patients may have received prior systemic chemotherapy. Such therapy must have been
completed at least 5 years prior to study entry and the patient has no evidence of
disease subsequent to such therapy. Patients must not have received neoadjuvant
chemotherapy for the present disease.
- Patients must have GOG performance status 0, 1, or 2.
- Patients must have an estimated survival greater than or equal to 3 months
- Patients who have met the pre-entry requirements specified in Section 7.0.
- Patients must have signed an approved informed consent and HIPAA authorization.
- Patients with clinical evidence of disease beyond the uterus, including presence of
suspicious aortic or inguinal nodes on imaging or clinical exam.
- Patients who have received previous vaginal, pelvic, or abdominal irradiation.
- Patients who received chemotherapy directed at the present disease.
- Patients who have circumstances that will not permit completion of this study or the
- Patients with renal abnormalities, such as pelvic kidney, horseshoe kidney, or renal
transplantation, that would require modification of surgical lymph node assessments.
- Patients with a history of other invasive malignancies, with the exception of
non-melanoma skin cancer within the last five years.
- Patients with GOG Performance Grade of 3 or 4.